Fractyl Health announces 6-month results from REVEAL-1 Cohort

Fractyl Health (GUTS) announced positive 6-month results from its open-label REVEAL-1 Cohort. The REVEAL-1 Cohort is an open-label study in individuals with obesity who have lost at least 15% of their total body weight on a GLP-1 medication and who either need or choose to discontinue GLP-1 therapy. The REVEAL-1 data show that patients who underwent a single Revita procedure after discontinuing GLP-1 therapy maintained both stable body weight and glycemic control through 6 months. The new results highlight Revita’s potential as a compelling first-in-class therapy for post-GLP-1 weight maintenance. Key Findings: Participants lost 24% total body weight on GLP-1 drugs prior to enrollment; Participants maintained stable weight after a single Revita procedure, with a mean total body weight change of 1.5% +/- 1.3% at 6 months; Minimal change in HbA1c levels was observed after the Revita procedure; Mean body weight and HbA1c curves showed a stable and durable trajectory over time; No procedure-related serious adverse events were observed; Average ablation length was approximately